Evidence map›Paper›PMID 35226174›Full record

ReviewJournal of gastroenterology2022

Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.

Katsuhiko Iwakiri, Yasuhiro Fujiwara, Noriaki Manabe, Eikichi Ihara, Shiko Kuribayashi, Junichi Akiyama, Takashi Kondo, Hiroshi Yamashita, Norihisa Ishimura, Yuichi Kitasako and 12 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 11 pooled it
34.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 11 syntheses or guidelines pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Uncut Roux-en-Y reconstruction after distal gastrectomy for gastric cancer.The Cochrane database of systematic reviews · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Therapeutic Evaluation ofNutrients · 2024
    Trial
  17. Trial
  18. Review
  19. Article
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Katsuhiko IwakiriGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan. k-iwa@nms.ac.jp.
Yasuhiro FujiwaraGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Noriaki ManabeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Eikichi IharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Shiko KuribayashiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Junichi AkiyamaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Takashi KondoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Hiroshi YamashitaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Norihisa IshimuraGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Yuichi KitasakoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Katsunori IijimaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Tomoyuki KoikeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Nobuo OmuraGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Tsutomu NomuraGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Osamu KawamuraGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Shuichi OharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Soji OzawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Yoshikazu KinoshitaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Satoshi MochidaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Nobuyuki EnomotoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Tooru ShimosegawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Kazuhiko KoikeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Gastroesophageal Reflux Disease", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
The Japanese Society of Gastroenterological Surgery · JPNippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Japan, with the increasing prevalence of gastroesophageal reflux disease (GERD) and growing public interest, the Japanese Society of Gastroenterology issued Evidence-based Clinical Practice Guidelines for GERD (1st edition) in 2009 and a revised 2nd edition in 2015. A number of studies on GERD were subsequently conducted in Japan and abroad, and vonoprazan, a potassium-competitive acid blocker (P-CAB), became available for the first time in Japan in February 2015. The revised 3rd edition (Japanese edition), which incorporates new findings and information, was published in April 2021. These guidelines are summarized herein, particularly sections related to the treatment of GERD. The important clinical issues addressed in the present revision are (i) the introduction of treatment algorithms that classify GERD into reflux esophagitis and non-erosive reflux disease, (ii) the clarification of treatment algorithms based on to the severity of reflux esophagitis, and (iii) the positioning of vonoprazan in the treatment for GERD. The present guidelines propose vonoprazan as the initial/maintenance treatment for severe reflux esophagitis. They also recommend vonoprazan or PPI as an initial treatment for mild reflux esophagitis and recommended PPI and proposed vonoprazan as maintenance treatment. These updated guidelines offer the best clinical strategies for GERD patients in Japan and hope that they will be of global use for the diagnosis and treatment for GERD.

Indexed as

Esophagitis, PepticGastroenterologyGastroesophageal RefluxEvidence-Based PracticeHumansProton Pump InhibitorsProton Pump InhibitorsAlgorithmGastroesophageal reflux disease (GERD)GuidelinesHeartburnJapanese traditional medicineNon-erosive reflux diseasePotassium-competitive acid blocker (P-CAB)Prokinetic drugProton pump inhibitorReflux esophagitisVonoprazan

Identifiers

PMID35226174
PMCPMC8938399
OpenAlexW4214617140

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.